Schizophrenia News From Medical News Today
Latest Health News and Medical News posted throughout the day, every day.
This blog is one of the best health, mental health, mental, schizophrenia blogs out there. Add this blog to My Feeds.
Dainippon Sumitomo Pharma America Announces FDA Acceptance Of Lurasidone New Drug Application For Treatment Of Schizophrenia
Mar 11, 2010 1:00am
Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), announced that the U.S. Food and Drug Administration (FDA) recently accepted for review the lurasidone New Drug Application (NDA) for the treatment of patients with acute schizophrenia. The NDA was submitted to FDA on...
Schizophrenia Gene Network Analysis Identifies Age-Associated Defects
Mar 2, 2010 2:00am
The underlying causes of the debilitating psychiatric disorder schizophrenia remain poorly understood. In a study published online in Genome Research, scientists have performed a powerful gene network analysis that has revealed surprising new insights into how gene regulation and age play a role in schizophrenia......
Alkermes Unveils Long-Acting Injectable Proprietary Platform For Treatment Of Schizophrenia And Other CNS Disorders
Feb 7, 2010 12:00am
Alkermes, Inc. (NASDAQ: ALKS) announced that it has developed a novel, proprietary LinkeRx™ technology platform to enable the creation of injectable extended-release versions of antipsychotics and other central nervous system (CNS) therapies......
Early Intervention Could Prevent Schizophrenia
Jan 29, 2010 5:00am
The onset of schizophrenia is not easy to predict. Although it is associated with as many as 14 genes in the human genome, the prior presence of schizophrenia in the family is not enough to determine whether one will succumb to the mind-altering condition. The disease also has a significant...
Duke To Lead Effort To Better Understand The Role Of Rare Genetic Variation In Clozapine-induced Agranulocytosis Using Whole Genome Sequencing
Jan 29, 2010 12:00am
The International Serious Adverse Events Consortium (SAEC) has announced that it will collaborate with Duke University's Center for Human Genome Variation to research the genetics of Clozapine-induced agranulocytosis (CIA), with the goal of identifying potential rare genetic variants predictive of this serious drug induced adverse event......
The Hidden Cost Of Schizophrenia
Jan 28, 2010 5:00am
People being treated for schizophrenia are more likely than the general population to have encounters with the criminal justice system in the US......
Childhood Clues To Adult Schizophrenia
Jan 23, 2010 12:00am
Years before adults develop schizophrenia, there is a pattern of cognitive difficulties they experience as children, including problems with verbal reasoning, working memory, attention and processing speed......
Blood Test For Schizophrenia Could Be Ready This Year
Jan 22, 2010 12:00am
A blood test for diagnosing schizophrenia - the most serious form of mental illness - could be available this year, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine. The disorder, with symptoms that can include hallucinations and delusional thoughts, affects more than...
Examining The Impact Of FDA Safety Warnings
Jan 12, 2010 3:00am
A study published in the Archives of Internal Medicine examines the impact of a safety warning issued by the Food and Drug Administration for commonly prescribed antipsychotic medications......
Race-Based Misdiagnosis Still Remains A Health Care Problem
Jan 8, 2010 12:00am
Black men are over-diagnosed with schizophrenia at least five times higher than any other group - a trend that dates back to the 1960s, according to new University of Michigan research......
EnVivo Enters Phase 2b Trials For Its EVP-6124 Compound In The Treatment Of Schizophrenia
Jan 6, 2010 2:00am
EnVivo Pharmaceuticals announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe......
Dainippon Sumitomo Pharma America Announces The NDA Submission Of Lurasidone To The FDA For The Treatment Of Schizophrenia
Jan 6, 2010 2:00am
Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia......
Before Or After Birth, Gene Linked To Mental Health Has Different Effects
Jan 6, 2010 12:00am
Scientists have long eyed mutations in a gene known as DISC1 as a possible contributor to schizophrenia and mood disorders, including depression and bipolar disorder......
Intra-Cellular Therapies Announces The Results Of A Phase I PET Study For ITI-007 For The Treatment Of Schizophrenia And Other Psychiatric Disorders
Dec 22, 2009 1:00am
Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and...
Alexza Announces Submission Of AZ-004 (Staccato(R) Loxapine) NDA
Dec 16, 2009 12:00am
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) to the US Food and Drug Administration (FDA). AZ-004 is an inhalation product candidate being developed for the rapid treatment of agitation in patients with schizophrenia or bipolar disorder......
Workings Of Anti-Psychotic Drugs In The Living Brain Revealed By New Biosensors
Dec 14, 2009 3:00am
Scientists have resolved a question about how a popular class of drugs used to treat schizophrenia works using biosensors that reveal previously hidden components of chemical communication in the brain......
Targacept Initiates Phase 2 Study Of TC-5619 In Cognitive Dysfunction In Schizophrenia
Dec 13, 2009 12:00am
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR TherapeuticsTM, announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia......
Late-Breaking Brain And Behavior Research Presented At ACNP Annual Meeting
Dec 12, 2009 12:00am
The 2009 American College of Neuropsychopharmacology Annual Meeting featured innovative research on PTSD, biomarkers for schizophrenia and treatment for gambling addiction. Study highlights included: Researchers Use New Techniques to Assess PTSD......
Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone Palmitate) Statistically Similar To RISPERDAL(R) CONSTA(R) (risperidone)
Dec 11, 2009 3:00am
Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week......
FDA Approves Lilly's Zyprexa For Two Adolescent Indications
Dec 5, 2009 1:00am
The U.S. Food and Drug Administration (FDA) approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old......
Schizophrenia Gene's Role May Be Broader, More Potent, Than Thought
Nov 21, 2009 12:00am
UCSF scientists studying nerve cells in fruit flies have uncovered a new function for a gene whose human equivalent may play a critical role in schizophrenia. Scientists have known that the mutated form of the human gene - one of three consistently associated with schizophrenia - mildly disrupts the transmission...
Otsuka Pharmaceutical Europe Ltd Withdraws Its Application For An Extension Of Indication For Abilify (aripiprazole), Europe
Nov 20, 2009 12:00am
The European Medicines Agency has been formally notified by Otsuka Pharmaceutical Europe Ltd of its decision to withdraw its application for an extension of indication for the centrally authorised medicine Abilify (aripiprazole) tablets, orodispersible tablets and oral solution......
Claim your "Top 100 Blogs" award now!
Top 100 Blogs Size: 125x125 px. Copy and paste the following code to your blog or website.